Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

NETWORK 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Biphenotypic, Acute 6Leukemia, Myeloid, Acute 5Carcinoma, Non-Small-Cell Lung 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lung Neoplasms 4Burkitt Lymphoma 4Wilms Tumor 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Osteosarcoma 3Neuroblastoma 3Ganglioneuroblastoma 3Teratoma 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Prostatic Neoplasms 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Hepatoblastoma 2Hematologic Neoplasms 2Fibrolamellar hepatocellular carcinoma 2Desmoid Tumors 2Carcinoma, Embryonal 2Anatomic Stage I Breast Cancer AJCC v8 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Rhabdomyosarcoma, Embryonal 1

Interventions

Magnetic Resonance Spectroscopy 4Doxorubicin 4Cyclophosphamide 4Vincristine 3Topotecan 3Stem Cell Transplantation 3Specimen Handling 3Radiation 3Platinum 3Melphalan 3Isotretinoin 3Congresses as Topic 3Cisplatin 3Busulfan 3Biopsy 33-Iodobenzylguanidine 31,2-diaminocyclohexaneplatinum II citrate 3sargramostim 2etoposide phosphate 2dinutuximab 2Etoposide 2Colony-Stimulating Factors 2Carboplatin 2lorlatinib 1Watchful Waiting 1Thiotepa 1Temozolomide 1Razoxane 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NETWORK × Ganglioneuroblastoma × Specimen Handling × Clear all
NCT06858501 2026-03-19

Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma

Children's Oncology Group

Phase 2 Not yet recruiting
84 enrolled
CNS

Ganglioneuroblastoma

NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Children's Oncology Group

Phase 3 Recruiting
750 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT04385277 2025-10-27

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

Children's Oncology Group

Phase 2 Active not recruiting
41 enrolled 13 charts
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡